Outpatient therapy of malignant ascites related to advanced gynecologic carcinomas with intraperitoneal application of the trifunctional antibody catumaxomab

Objectives: Catumaxomab (CATU) is a trifunctional antibody approved for the treatment (Tx) of malignant ascites (MA) related to EpCAM-positive tumors. CATU is mostly administered in a hospital. We report on our single-institution experience with outpatient CATU in patients (pts) with MA due to various gynecologic carcinomas. Methods: 26 patients were included: epithelial ovarian cancer (14), metastatic breast cancer (6), endometrial cancer (3), other (3). Patients had failed a median of 4 prior systemic Tx (range: 1 – 12). CATU was administered at four planned increasing doses (i.e., 10, 20, 50, and 150 µg) give…